To assess whether the four novel MMR gene variants were indeed pathogenic, we performed immunohistochemistry (IHC) on the respective tumor tissues using antibodies directed against the MLH1, PMS2, MSH2 and MSH6 proteins. Here, MSH6 is linked to neoplasm.